JP2015029905A - 生物組織の調製方法 - Google Patents
生物組織の調製方法 Download PDFInfo
- Publication number
- JP2015029905A JP2015029905A JP2014130867A JP2014130867A JP2015029905A JP 2015029905 A JP2015029905 A JP 2015029905A JP 2014130867 A JP2014130867 A JP 2014130867A JP 2014130867 A JP2014130867 A JP 2014130867A JP 2015029905 A JP2015029905 A JP 2015029905A
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- decellularization
- detergent
- surfactin
- lipopeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 35
- 239000003599 detergent Substances 0.000 claims abstract description 36
- 102000008186 Collagen Human genes 0.000 claims abstract description 21
- 108010035532 Collagen Proteins 0.000 claims abstract description 21
- 229920001436 collagen Polymers 0.000 claims abstract description 21
- 108010028921 Lipopeptides Proteins 0.000 claims abstract description 20
- 239000000835 fiber Substances 0.000 claims abstract description 16
- 210000003709 heart valve Anatomy 0.000 claims abstract description 14
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 11
- 238000004132 cross linking Methods 0.000 claims abstract description 8
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 29
- AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 claims description 22
- NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 claims description 22
- NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- -1 iturin Chemical compound 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- ZQVJBRJGDVZANE-MXDMHAPNSA-N (2s)-2-[(3s,6s,9z,12s,15s,18s,21r,24r,27s)-18,21-bis(2-aminoethyl)-12-benzyl-3-[(1s)-2-chloro-1-hydroxyethyl]-15-[3-(diaminomethylideneamino)propyl]-9-ethylidene-27-[[(3s)-3-hydroxydodecanoyl]amino]-24-(hydroxymethyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa Chemical compound N1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](O)CCCCCCCCC)COC(=O)[C@H]([C@H](O)CCl)NC(=O)[C@H]([C@H](O)C(O)=O)NC(=O)\C(=C\C)NC(=O)[C@@H]1CC1=CC=CC=C1 ZQVJBRJGDVZANE-MXDMHAPNSA-N 0.000 claims description 7
- HXMCERBOSXQYRH-KSVGBCIHSA-N Arthrofactin Chemical compound CCCCCCCC1CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)O1 HXMCERBOSXQYRH-KSVGBCIHSA-N 0.000 claims description 7
- 108010020326 Caspofungin Proteins 0.000 claims description 7
- 108010013198 Daptomycin Proteins 0.000 claims description 7
- 108010049047 Echinocandins Proteins 0.000 claims description 7
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 7
- 108010040201 Polymyxins Proteins 0.000 claims description 7
- ZQVJBRJGDVZANE-UHFFFAOYSA-N Syringomycin Natural products N1C(=O)C(CCCN=C(N)N)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CO)NC(=O)C(NC(=O)CC(O)CCCCCCCCC)COC(=O)C(C(O)CCl)NC(=O)C(C(O)C(O)=O)NC(=O)C(=CC)NC(=O)C1CC1=CC=CC=C1 ZQVJBRJGDVZANE-UHFFFAOYSA-N 0.000 claims description 7
- 108010066374 arthrofactin Proteins 0.000 claims description 7
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 claims description 7
- 229960003034 caspofungin Drugs 0.000 claims description 7
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims description 7
- 229960005484 daptomycin Drugs 0.000 claims description 7
- 108010078552 syringomycin Proteins 0.000 claims description 7
- 239000012459 cleaning agent Substances 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- QJYNZEYHSMRWBK-NIKIMHBISA-N 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose Chemical compound OC1=C(O)C(O)=CC(C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 QJYNZEYHSMRWBK-NIKIMHBISA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 claims description 2
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 claims description 2
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 claims description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 2
- 229920001991 Proanthocyanidin Polymers 0.000 claims description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 2
- 239000007975 buffered saline Substances 0.000 claims description 2
- 150000001718 carbodiimides Chemical class 0.000 claims description 2
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 claims description 2
- 235000002949 phytic acid Nutrition 0.000 claims description 2
- 229920001864 tannin Polymers 0.000 claims description 2
- 235000018553 tannin Nutrition 0.000 claims description 2
- 239000001648 tannin Substances 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 92
- 230000008602 contraction Effects 0.000 description 10
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 9
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000011777 magnesium Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 230000002308 calcification Effects 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000006177 biological buffer Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002296 pyrolytic carbon Substances 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/367—Muscle tissue, e.g. sphincter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Prostheses (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
・適切な洗浄剤で組織を脱細胞化することと、その後、
・適切な架橋剤で組織のコラーゲン繊維を架橋することと、が含まれる。
(式中、nは10から12、Glu、Leu、Val、Aspはそれぞれアミノ酸のグルタミン酸、ロイシン、バリンおよびアスパラギン酸を示す)。
Claims (9)
- 医療用の組織を調製する方法、特に人工心臓弁に使用する組織の調製方法において、少なくとも以下の工程:
・適切な洗浄剤で組織を脱細胞化することと、その後、
・適切な架橋剤で組織のコラーゲン繊維を架橋することと、を含み、前記脱細胞化用の洗浄剤は、両親媒性を有する少なくとも一つのリポペプチドであって、親水性の基礎構造と疎水性の側鎖とを包含するリポペプチドを含んでなる、ことを特徴とする、方法。 - 請求項1に記載の方法において、前記脱細胞化用の洗浄剤は、環状リポペプチド、特にサーファクチンを含んでなる、ことを特徴とする、方法。
- 請求項1または2に記載の方法において、前記洗浄剤は、サーファクチン、ダプトマイシン、カスポファンギン、アルスロファクチン、エキノカンジン、イツリン、シリンゴマイシン、シリンゴペプチドおよび/またはポリミキシンを含んでなる、ことを特徴とする、方法。
- 請求項1〜3のいずれか一項に記載の方法において、前記架橋剤は、グルタルアルデヒド、カルボジイミド、ホルムアルデヒド、グルタルアルデヒドアセタル、アシルアジド、シアンイミド、ゲニピン、タンニン、ペンタガロイルグルコース、フィチン酸塩、プロアンソシアニジン、ロイテリンおよび/またはエポキシド化合物を含んでなる、ことを特徴とする、方法。
- 請求項1〜4のいずれか一項に記載の方法において、前記組織は、脱細胞化の前および/または後に、適切な溶媒、特に緩衝生理食塩溶液および/またはアルコール溶液で少なくとも一度リンスされる、ことを特徴とする、方法。
- 請求項1〜5のいずれか一項に記載の方法において、前記洗浄剤は、100mg/Lから2000mg/L、好ましくは500mg/Lから700mg/L、特に好ましくは600mg/Lの濃度を有する少なくとも一つのリポペプチド特にサーファクチンを包含する緩衝液、特にリン酸緩衝液を含んでなる、ことを特徴とする、方法。
- 生物組織、特に心臓弁プロテーゼ用生物組織の前記脱細胞化用洗浄剤として、両親媒性を有し、親水性の基礎構造と疎水性の側鎖とを包含する少なくとも一つのリポペプチドを含んでなる溶液の使用。
- 請求項7に記載の使用において、前記溶液が、サーファクチン、ダプトマイシン、カスポファンギン、アルスロファクチン、エキノカンジン、イツリン、シリンゴマイシン、シリンゴペプチドおよび/またはポリミキシンを含んでなる、ことを特徴とする、使用。
- 請求項8に記載の使用において、サーファクチン、ダプトマイシン、カスポファンギン、アルスロファクチンおよび/またはエキノカンジン、イツリン、シリンゴマイシン、シリンゴペプチドポリミキシンが、緩衝液、特にリン酸緩衝液に溶解される、ことを特徴とする、使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13178696.4A EP2832379B1 (de) | 2013-07-31 | 2013-07-31 | Verfahren zur Aufbereitung von biologischem Gewebe |
EP13178696.4 | 2013-07-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015029905A true JP2015029905A (ja) | 2015-02-16 |
JP5856239B2 JP5856239B2 (ja) | 2016-02-09 |
Family
ID=48900840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014130867A Active JP5856239B2 (ja) | 2013-07-31 | 2014-06-26 | 生物組織の調製方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9402934B2 (ja) |
EP (1) | EP2832379B1 (ja) |
JP (1) | JP5856239B2 (ja) |
CN (2) | CN104338180A (ja) |
AU (1) | AU2014203338B2 (ja) |
CA (1) | CA2854529A1 (ja) |
HK (1) | HK1203857A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018534976A (ja) * | 2015-10-07 | 2018-11-29 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | 培養細胞小葉材料 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102015108952A1 (de) * | 2015-06-08 | 2016-12-08 | Biotronik Ag | Verfahren zur Aufbereitung von biologischem Gewebe |
US10537662B2 (en) * | 2013-07-31 | 2020-01-21 | Biotronik Ag | Method for preparing biological tissue |
CN105233341A (zh) * | 2015-10-19 | 2016-01-13 | 北京迈迪顶峰医疗科技有限公司 | 一种人工生物带瓣膜血管及其制备方法 |
US11737867B2 (en) | 2015-11-03 | 2023-08-29 | Biotronik Ag | Method for reducing paravalvular leaks with decellularized tissue |
DE102015118789A1 (de) | 2015-11-03 | 2017-05-04 | Biotronik Ag | Verfahren zur Reduktion von paravalvulären Leckagen mit dezellularisiertem Gewebe |
US20170173214A1 (en) * | 2015-12-21 | 2017-06-22 | Medtronic Vascular, Inc. | Methods for preparing dry cross-linked tissue |
EP3318288A1 (en) * | 2016-11-07 | 2018-05-09 | Biotronik AG | Method for preparing material from biological tissue |
CN107158466A (zh) * | 2017-07-03 | 2017-09-15 | 山东大学齐鲁医院 | 一种京尼平交联脱细胞神经支架及其制备方法与应用 |
CN107674826B (zh) * | 2017-09-04 | 2020-10-27 | 陕西众兴高科生物科技有限公司 | 一种液体菌种培养器 |
CN110604126A (zh) * | 2018-06-14 | 2019-12-24 | 宁波化奇工程技术有限公司 | 一种非甲醛环保病理组织固定剂 |
CN110152065B (zh) * | 2019-06-04 | 2020-03-10 | 四川大学 | 一种仿生微纳叠层疏水生物瓣膜及其制备方法 |
CN112870444A (zh) * | 2021-01-25 | 2021-06-01 | 上海翰凌医疗器械有限公司 | 一种改性生物组织材料及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06261933A (ja) * | 1992-02-12 | 1994-09-20 | Lifecell Corp | 移植用にコラーゲンベース組織を加工処理、保存するための方法 |
WO2004052417A1 (de) * | 2002-12-06 | 2004-06-24 | Auto Tissue Gmbh | Verfahren zur herstellung von bioprothesen |
JP2004531291A (ja) * | 2000-12-20 | 2004-10-14 | オート・ティッシュ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | バイオプロテーゼ製造用外来材料のデセルラライズ方法 |
WO2005063314A1 (ja) * | 2003-12-26 | 2005-07-14 | Cardio Incorporated | 脱細胞化組織およびその作成方法 |
WO2005118014A2 (en) * | 2004-06-01 | 2005-12-15 | Medtronic, Inc. | Decellurisation processes for making bioprotheses |
JP2011507608A (ja) * | 2007-12-19 | 2011-03-10 | エシコン・インコーポレイテッド | 脱細胞化網マトリックス及びその使用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100360190C (zh) * | 2005-11-30 | 2008-01-09 | 中国科学院上海硅酸盐研究所 | 具有生物活性的人工生物瓣瓣膜的制备方法 |
CN101496913B (zh) * | 2008-01-31 | 2012-09-26 | 中国人民解放军总医院 | 组织工程用软骨细胞外基质三维多孔海绵支架及其制备方法 |
CN101224313B (zh) * | 2008-02-04 | 2012-02-15 | 中国科学院上海硅酸盐研究所 | 采用槲皮素交联制备人工生物心脏瓣膜材料的方法 |
CN102575229A (zh) * | 2009-08-11 | 2012-07-11 | 约翰霍普金斯大学 | 用于植入经加工的脂肪组织和经加工的脂肪组织产品的组合物和方法 |
CN101690829B (zh) * | 2009-08-31 | 2013-09-18 | 中国科学院上海硅酸盐研究所 | 一种可再细胞化的生物瓣瓣膜材料的制备方法 |
WO2011109433A2 (en) | 2010-03-01 | 2011-09-09 | Vela Biosystems Llc | Tissue for prosthetic implants and grafts, and methods associated therewith |
ES2726105T3 (es) * | 2011-12-20 | 2019-10-01 | Lifecell Corp | Productos de tejido fluidizable |
BR112014018047B1 (pt) * | 2012-01-24 | 2019-11-26 | Lifecell Corp | composição de tratamento de tecido |
-
2013
- 2013-07-31 EP EP13178696.4A patent/EP2832379B1/de active Active
-
2014
- 2014-06-16 CA CA2854529A patent/CA2854529A1/en active Pending
- 2014-06-19 AU AU2014203338A patent/AU2014203338B2/en not_active Ceased
- 2014-06-26 JP JP2014130867A patent/JP5856239B2/ja active Active
- 2014-07-23 CN CN201410352864.XA patent/CN104338180A/zh active Pending
- 2014-07-23 CN CN201910773284.0A patent/CN110384827A/zh active Pending
- 2014-07-26 US US14/341,783 patent/US9402934B2/en active Active
-
2015
- 2015-05-15 HK HK15104649.0A patent/HK1203857A1/xx unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06261933A (ja) * | 1992-02-12 | 1994-09-20 | Lifecell Corp | 移植用にコラーゲンベース組織を加工処理、保存するための方法 |
JP2004531291A (ja) * | 2000-12-20 | 2004-10-14 | オート・ティッシュ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | バイオプロテーゼ製造用外来材料のデセルラライズ方法 |
WO2004052417A1 (de) * | 2002-12-06 | 2004-06-24 | Auto Tissue Gmbh | Verfahren zur herstellung von bioprothesen |
WO2005063314A1 (ja) * | 2003-12-26 | 2005-07-14 | Cardio Incorporated | 脱細胞化組織およびその作成方法 |
WO2005118014A2 (en) * | 2004-06-01 | 2005-12-15 | Medtronic, Inc. | Decellurisation processes for making bioprotheses |
JP2011507608A (ja) * | 2007-12-19 | 2011-03-10 | エシコン・インコーポレイテッド | 脱細胞化網マトリックス及びその使用 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018534976A (ja) * | 2015-10-07 | 2018-11-29 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | 培養細胞小葉材料 |
Also Published As
Publication number | Publication date |
---|---|
EP2832379A1 (de) | 2015-02-04 |
CA2854529A1 (en) | 2015-01-31 |
US9402934B2 (en) | 2016-08-02 |
CN104338180A (zh) | 2015-02-11 |
AU2014203338A1 (en) | 2015-02-19 |
CN110384827A (zh) | 2019-10-29 |
JP5856239B2 (ja) | 2016-02-09 |
US20150037433A1 (en) | 2015-02-05 |
EP2832379B1 (de) | 2015-07-22 |
AU2014203338B2 (en) | 2018-08-02 |
HK1203857A1 (en) | 2015-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5856239B2 (ja) | 生物組織の調製方法 | |
JP5599722B2 (ja) | 脱細胞化網マトリックス及びその使用 | |
ES2881079T3 (es) | Método de descelularización de injertos de tejidos | |
US7674289B2 (en) | Biological artificial ligament and method of making | |
Mathapati et al. | Biomimetic acellular detoxified glutaraldehyde cross-linked bovine pericardium for tissue engineering | |
RU2630979C2 (ru) | Способ стерилизации | |
CN103068413A (zh) | 用于使组织基质成形的方法 | |
US10537662B2 (en) | Method for preparing biological tissue | |
EP2320966B1 (en) | Biological nasal bridge implant and method of manufacture | |
EP3393535A1 (en) | Methods for preparing dry cross-linked tissue | |
ES2842505T3 (es) | Corneas acelulares, métodos de producción de las mismas y usos de las mismas | |
US20160354519A1 (en) | Method for preparing biological tissue | |
Sokol et al. | Prospects for application of bovine pericardial scaffold for cardial surgery | |
Lau | Decellularization of fish skin for tissue engineering applications | |
Sharma et al. | Tissue Scaffolds Derived from Pig Gallbladder | |
Kumar et al. | Naturally Derived Biomaterials: An Overview | |
CN110960731A (zh) | 一种医用外科生物补片的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150728 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20150728 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20150818 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150915 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151013 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151029 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151116 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151203 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151210 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5856239 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |